SERUM PROTEOMIC PREDICTION OF OUTCOMES IN ADVANCED NSCLC PATIENTS TREATED WITH ERLOTINIB/PLACEBO IN THE NCIC CLINICAL TRIALS GROUP BR.21 TRIAL

被引：0
|
作者：
Carbone, D. P. [1 ]
Seymour, L. [2 ]
Ding, K. [3 ]
Roder, H. [4 ]
Tsao, M. [5 ]
Shepherd, F. A. [5 ]
机构：
[1] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN USA
[2] Queens Univ, Ncic Ctg, Toronto, ON, Canada
[3] Queens Univ, Commun Hlth & Epidemiol, Kingston, ON K7L 3N6, Canada
[4] Biodesix Inc, Broomfield, CO USA
[5] Princess Margaret Hosp, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [21] Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib
    Jackman, D. M.
    Sequist, L. V.
    Cioffredi, L.
    Ruiz, M. Gallegos
    Janne, P. A.
    Giaccone, G.
    Miller, V. A.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] A Phase 2 Study of Platinum and Gemcitabine in Patients With Advanced Salivary Gland Cancer A Trial of the NCIC Clinical Trials Group
    Laurie, Scott A.
    Siu, Lillian L.
    Winquist, Eric
    Maksymiuk, Andrew
    Harnett, Erica L.
    Walsh, Wendy
    Tu, Dongsheng
    Parulekar, Wendy R.
    CANCER, 2010, 116 (02) : 362 - 368
  • [23] Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
    Laurie, S. A.
    Solomon, B. J.
    Seymour, L.
    Ellis, P. M.
    Goss, G. D.
    Shepherd, F. A.
    Boyer, M. J.
    Arnold, A. M.
    Clingan, P.
    Laberge, F.
    Fenton, D.
    Hirsh, V.
    Zukin, M.
    Stockler, M. R.
    Lee, C. W.
    Chen, E. X.
    Montenegro, A.
    Ding, K.
    Bradbury, P. A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (04) : 706 - 712
  • [24] Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Santoro, Armando
    Ross, Paul
    Gane, Edward
    Vogel, Arndt
    Jeffers, Michael
    Meinhardt, Gerold
    Pena, Carol E. A.
    CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4870 - 4879
  • [25] Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG].
    Moore, MJ
    Goldstein, D
    Hamm, J
    Figer, A
    Hecht, J
    Gallinger, S
    Au, H
    Ding, K
    Christy-Bittel, J
    Parulekar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1S - 1S
  • [26] A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy.: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial.
    Shepherd, FA
    Pereira, J
    Ciuleanu, TE
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Bezjak, A
    Tu, D
    Santabárbara, P
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 622S - 622S
  • [27] An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer.
    Tsao, M.
    Zhu, C.
    Sakurada, A.
    Zhang, T.
    Whitehead, M.
    Kamel-Reid, S.
    Ding, K.
    Seymour, L.
    Shepherd, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 365S - 365S
  • [28] Erlotinib Plus Either Pazopanib or Placebo in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: A Randomized, Placebo-Controlled Phase 2 Trial With Correlated Serum Proteomic Signatures
    Spigel, David R.
    Burris, Howard A., III
    Greco, F. Anthony
    Shih, Kent C.
    Gian, Victor G.
    Lipman, Andrew J.
    Daniel, Davey B.
    Waterhouse, David M.
    Finney, Lindsey
    Heymach, John V.
    Hainsworth, John D.
    CANCER, 2018, 124 (11) : 2355 - 2364
  • [29] Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials
    Osarogiagbon, Raymond U.
    Cappuzzo, Federico
    Ciuleanu, Tudor
    Leon, Larry
    Klughammer, Barbara
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (04) : 465 - 474
  • [30] Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
    Goss, Glenwood D.
    Arnold, Andrew
    Shepherd, Frances A.
    Dediu, Mircea
    Ciuleanu, Tudor-Eliade
    Fenton, David
    Zukin, Mauro
    Walde, David
    Laberge, Francis
    Vincent, Mark D.
    Ellis, Peter M.
    Laurie, Scott A.
    Ding, Keyue
    Frymire, Eliot
    Gauthier, Isabelle
    Leighl, Natasha B.
    Ho, Cheryl
    Noble, Jonathan
    Lee, Christopher W.
    Seymour, Lesley
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 49 - 55
12345